InvestorsHub Logo
Followers 827
Posts 119581
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 1830

Monday, 01/13/2020 5:45:18 PM

Monday, January 13, 2020 5:45:18 PM

Post# of 2953
ENTA—Re: hMPV

This excerpt from ENTA’s 1/9/20 PR (#msg-153206240) is being discussed on the JPM webcast:

We are also introducing today our newest program, which is for treatment of hMPV, a pathogen identified in 2001 that causes upper and lower respiratory tract infections in young children and the elderly, as well as COPD, asthma, and immunocompromised patients.

“hMPV” is human metapneumovirus, which is similar to RSV and has no approved vaccines or treatments.

ENTA's hMPV program is in the lead-optimization stage.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News